Telitacicept in myasthenia gravis: a systematic review of clinical outcomes, steroid-sparing effects, and safety.

What was studied

This review looked at telitacicept in myasthenia gravis. This is an autoimmune disease of nerves and muscles. Long-term control is hard for some people. The drug blocks the signals BAFF and APRIL. The review asked about benefit, steroid-sparing effects and safety. The team searched PubMed, Scopus, Embase and other sources up to 19 January 2026. Studies differed too much to pool. So results were put in words.

What they found

The review included a mix of studies. There was a randomised trial, cohort studies, case series and case reports. The evidence generally suggested better disease scores. These included QMG and MG-ADL. In the randomised trial, QMG fell by about 7-10 points at 24 weeks. Several observational studies reported lower steroid needs. Side effects were generally mild and brief.

What it means for patients

The authors say the drug may give benefits and steroid-sparing effects in selected patients. They say more well-designed randomised trials are needed. These should test efficacy, long-term safety and its place in care.

Why it is not certain yet

Most studies were retrospective or uncontrolled. Long-term safety was hard to judge. Samples were small and follow-up was short. The studies differed in design, patients, treatment and outcomes. Only one randomised trial was included. A review can only be as good as the studies in it.

Source

Telitacicept in myasthenia gravis: a systematic review of clinical outcomes, steroid-sparing effects, and safety.

We restate facts from the source record in our own words. The original wording belongs to its publisher.